TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean SC cross-sectional area and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of autoantibodies for breast cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in weekly itch severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in weekly urticaria activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Injurious Behavior (SIB)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Local and Systemic Adverse Events in Year 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local and Systemic Adverse Events in Year 2
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Body Core Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Water Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving > 50% seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of AHI algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of combined rituximab and subcutaneous alemtuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance rate of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HCV LVL G1 Participants Who Relapsed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological outcome assessed by the extended Glasgow Outcome Scale (GOSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupillary reflex measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAPD measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous pupillary oscillation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Severity of Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in AM/PM PRIOR Major Symptoms Score (Mss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Opacification of the Maxillary Sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of event-related potentials (ERPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of resting EEG power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of lateralization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge about Dietary Supplements
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of Dietary Supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of consultations authorized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Progression-free survival after 6 months
Endpoint domain: Mortality/survival
Primary endpoint: number of patients requiring a second surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of infants tolerating the formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Diffusing Capacity Carbon Monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood loss after total hip arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Distance from home to treatment center
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Nasal Obstruction and Septoplasty Effectiveness (NOSE) Instrument Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic effects of far infrared radiation on osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RNFL thickness in the affected eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time spent in the desired pCO2 range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of children's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of children's behavioral-emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of parent's mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Lumbar Spine Bone Mineral Density Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with pediatric community acquired pneumonia (pedCAP)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of pediatric community acquired pneumonia (pedCAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Self-reported Physical Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mTOR inhibitor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in METs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Augmentation Index Percent Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gambling symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain reported by the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) as of Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid relapse
Endpoint domain: Mortality/survival
Primary endpoint: Methadone treatment retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression, Anxiety, and Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum ACE Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Carpal Tunnel Syndrome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: remission status after eradication therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous complete remission (CCR) during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission status after radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous complete remission after radiation therapy during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendicitis requiring surgery or other intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Surfactant protein B serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-related complications: phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter-related complications: infiltration
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter-related complications: occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of toxicity of the combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in speed of processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perception of walking ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of a genetic anomaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of a genetic mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVEF (radionuclide ventriculography)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vaccine-related reaction events and other adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of serum antibody and mucosal antibody induced by the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: 24 Hour Postoperative Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of T Lymphocyte Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time for Prostatic Artery Catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aid secretion clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FeNO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily step count
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amount of drain at postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pulmonary airflow physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in pulmonary gas exchange physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores for the Wijma Delivery Expectancy Questionnaire (W-DEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: heart failure readmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional performance as assessed by single-leg hop for distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DNA fragmentation index (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of fusion mass bridging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of adverse surgical outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Meibomian Gland Secretion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported occurrence of fall
Endpoint domain: Adverse events/effects
Primary endpoint: Serum creatinine less than 1.5 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion complete protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: S-amlodipine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of myocardial dysfunction using left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in myocardial function using left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of risk of developing cardiotoxicity using left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of subclinical cardiac dysfunction using left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impact on medical management of cardiotoxicity using left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patellar tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Semen volume at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline Total sperm number at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline Sperm concentration at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Nocturnal Melatonin Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of healthcare associated infections
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Concentration of Velpatasvir in Maternal Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Sofosbuvir in Maternal Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of GS-331007 in Maternal Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Maternal Plasma Concentration Versus Time Curve of Velpatasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Maternal Plasma Concentration Versus Time Curve of Sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants properly diagnosed with genuine stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-curve of metformin absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival in the Overall Population
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival in the Female Population
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: reduction of systemic levels of oxidative stress markers and adhesion molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of endometrial lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dopamine D2 receptor availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 6 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal inspiratory and expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fear of activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transpulmonary driving pressure (TpDp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterisation of exhaled breath composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of oxidation of 13C phenylalanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Levels of Pain and Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate of rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FLACC pediatric pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Lesion Patency Through 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Safety Composite of Freedom From Death, Amputation, and Target Vessel Revascularization (TVR)
Endpoint domain: Mortality/survival
Primary endpoint: NK-cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tuberculin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inflammatory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SKAMP-DS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Choice Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Four Choice Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in X-Axis Intercept of ST-HR Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of Surgical Site Occurrence Requiring Procedural Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of Hernias
Endpoint domain: Adverse events/effects
Primary endpoint: cardiovascular morbidity/mortality
Endpoint domain: Mortality/survival
Primary endpoint: IFN-g ELISPOT reversion (Qualitative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-g ELISPOT reversion (Quantitative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Hb Change From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Hb Increment of at Least 1.0 gm/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients Achieving Correction of Anemia (Hb >11.0 gm/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Height for Age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Body Weight for Age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of DI-Leu16-IL2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With a DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Psychomotor Vigilance Task (PVT) Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total inspiratory resistance Rstat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dry Eye Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry Eye Symptom Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tear Film Break Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Function Assessment
Endpoint domain: Life impact
Endpoint subdomain: Visual functioning
Primary endpoint: AUC0-72h in fed state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72h in fasted state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of memantine in fed state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of memantine in fasted state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on sustained attention task (CPT-IP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patients' clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes